Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Journal Articles

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Ri Liesner, Ellis J. Neufeld, MD

Blood (2019) 134 (Supplement_1): 903.

https://doi.org/10.1182/blood-2019-125520

Published: 2019

Journal Articles

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Johannes Oldenburg, MD PhD, Anna Pavlova, MD PhD, Susan Halimeh, MD, Robert Klamroth, Joris Versteden, Martina Jansen, Larisa Belyanskaya, PhD

Blood (2018) 132 (Supplement 1): 5034.

https://doi.org/10.1182/blood-2018-99-116577

Published: 2018

Journal Articles

Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study

Flora Peyvandi, MD PhD, Bruce A. Schwartz, Sigurd Knaub

Blood (2018) 132 (Supplement 1): 2502.

https://doi.org/10.1182/blood-2018-99-116440

Published: 2018

Journal Articles

Final Results from a Non-Interventional Safety and Efficacy Study of a VWF/FVIII Concentrate (wilate ® ) in Patients with Von Willebrand Disease

Hassan M. Yaish, MD, Maria Sol Cruz, MD, Kay Decker, Eva M.K. Zetterberg, MD PhD, Sylvia Werner, Mariko Hashimoto, Sigurd Knaub, George M. Rodgers, MD PhD

Blood (2018) 132 (Supplement 1): 1182.

https://doi.org/10.1182/blood-2018-99-118069

Published: 2018

Journal Articles

Temporary and Permanent Inferior Vena Cava Filters in the Oncology Population

Suneel Deepak Kamath, MD, Elizabeth H. Cull, MD, Brady L. Stein, MD, Robert Lewandowski, MD, Brandon McMahon, MD

Blood (2016) 128 (22): 1423.

https://doi.org/10.1182/blood.V128.22.1423.1423

Published: 2016

Journal Articles

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Bruce A. Schwartz, PhD, Cecil Ross, MD, Bella Madan, MD, Toshko Jelev Lissitchkov, MD, Mehran Karimi, MD, Sigurd Knaub, Flora Peyvandi, MD PhD

Blood (2016) 128 (22): 1404.

https://doi.org/10.1182/blood.V128.22.1404.1404

Published: 2016

Journal Articles

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Blood (2016) 128 (22): 327.

https://doi.org/10.1182/blood.V128.22.327.327

Published: 2016

Journal Articles

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Blood (2016) 128 (5): 630–637.

https://doi.org/10.1182/blood-2016-01-687434

Published: 2016

Includes: Supplemental data

Journal Articles

Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion

Claudia Djambas Khayat, MD BS, Johnny N. Mahlangu, MD, Ross I Baker, MD, Cindy A. Leissinger, MD, Elena Santagostino, MD PhD, Debra M. Bensen-Kennedy, MD, Katie St. Ledger, MS, Alex Veldman, MD, Ingrid Pabinger, MD

Blood (2015) 126 (23): 3525.

https://doi.org/10.1182/blood.V126.23.3525.3525

Published: 2015

Journal Articles

Temporary Vena Cava Filters in Oncology Patients

Elizabeth H Cull, MD, Robert Lewandowski, MD, Brady L Stein, MD, Brandon McMahon, MD

Blood (2014) 124 (21): 4247.

https://doi.org/10.1182/blood.V124.21.4247.4247

Published: 2014

Journal Articles

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Annie Borel-Derlon, MD, PhD, Augusto B. Federici, MD, Jenny Goudemand, MD, PhD, Catherine Chatelanaz, Celine Henriet, Françoise Bridey

Blood (2011) 118 (21): 383.

https://doi.org/10.1182/blood.V118.21.383.383

Published: 2011

Journal Articles

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

Andrew Peng Yu, PhD, Arielle G Bensimon, BA, Maryna Marynchenko, MBA, Eric Qiong Wu, PhD, Madhav Namjoshi, PhD, Amy Guo, PhD, Solveig G Ericson, MD, PhD, Noopur Raje, MD

Blood (2010) 116 (21): 1956.

https://doi.org/10.1182/blood.V116.21.1956.1956

Published: 2010

Journal Articles

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, PhD, Amanda C. O’Brien, Brooke Hayward, SM, Steven Arkin, MD, David A. Roth, MD

Blood (2008) 112 (11): 1229.

https://doi.org/10.1182/blood.V112.11.1229.1229

Published: 2008

Journal Articles

Defining Severity for Rare Factor Deficiencies. Insights from the North American Rare Bleeding Disorder Registry(NARBDR).

Suchitra S Acharya, MD, Donna DiMichele, MD

Blood (2008) 112 (11): 2276.

https://doi.org/10.1182/blood.V112.11.2276.2276

Published: 2008

Journal Articles

Steel to heal? MPD surgical conundrums

Ruben A. Mesa

Blood (2008) 111 (2): 474.

https://doi.org/10.1182/blood-2007-10-118034

Published: 2008

Journal Articles

Efficacy and Safety of ReFacto AF for Surgical Hemostasis in Previously Treated Patients with Severe Hemophilia A.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, Mona El-Hashimy, MD, David A. Roth, MD, Steven Arkin, MD

Blood (2007) 110 (11): 3960.

https://doi.org/10.1182/blood.V110.11.3960.3960

Published: 2007

Journal Articles

von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate Is Safe and Effective for Management of Elective Surgery in Adults and Children with von Willebrand Disease (VWD): Combined Results of United States (US) and European (EU) Studies.

Joan Cox Gill, MD, Humate-P Surgery Study Investigators

Blood (2007) 110 (11): 2142.

https://doi.org/10.1182/blood.V110.11.2142.2142

Published: 2007

Journal Articles

An Exercise Training Programme Produces Significant Improvements in Quality of Life (QoL), Muscle Strength and Cardiorespiratory Function in Patients with Myeloma.

Lara J. Groeneveldt, BSc, Rachel Garrod, PhD, Kwee L. Yong, MD, Flora Dangwa, RGN, Andrew P. Jewell, PhD, Ken van Someren, PhD, Neil Rabin, MD, Lisa Nicholls, RGN, Shirley P. D’Sa, MD

Blood (2007) 110 (11): 3323.

https://doi.org/10.1182/blood.V110.11.3323.3323

Published: 2007

Journal Articles

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

Jerry Sherman Powell, MD, Thierry Lambert, MD, F. Hernández Navarro, MD, Michael Recht, MD, Sharon T. Sullivan, PhD, Chandrasekhar Udata, PhD, Leslie C. Lilly, BSN, RN, David A. Roth, MD, The rFIX-R Study Group

Blood (2005) 106 (11): 4076.

https://doi.org/10.1182/blood.V106.11.4076.4076

Published: 2005

NARROW

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Inhibitor Development with Simoctocog Alfa in Previously Untreated Patients with Severe Haemophilia a: Final Results of the Nuprotect Study

Practical Utilisation of Octapharma FVIII Concentrates in Previously Untreated and Minimally Treated Haemophilia a Patients Entering Routine Clinical Treatment with Nuwiq ® , Octanate ® or Wilate ® — the Protect-NOW Study

Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study

Final Results from a Non-Interventional Safety and Efficacy Study of a VWF/FVIII Concentrate (wilate ® ) in Patients with Von Willebrand Disease

Temporary and Permanent Inferior Vena Cava Filters in the Oncology Population

Efficacy of Human Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and to Prevent Bleeding during and after Surgery in Subjects with Congenital Fibrinogen Deficiency

Inhibitor Development in Previously Untreated Patients with Severe Hemophilia a Treated with Nuwiq ® , a New Generation Recombinant FVIII of Human Origin

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Rviii-Singlechain in Surgical Prophylaxis: Efficacy and Safety of Continuous and Bolus Infusion

Temporary Vena Cava Filters in Oncology Patients

Clinical Use of a Von Willebrand Factor with a Low FVIII Content in Von Willebrand Disease Patients Undergoing Surgical Procedures or Deliveries: Results From 5 Prospective Multicenter Studies

Comparison of Skeletal Complications and Treatment Patterns Associated with Early Versus Delayed Zoledronic Acid Therapy In Multiple Myeloma

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Defining Severity for Rare Factor Deficiencies. Insights from the North American Rare Bleeding Disorder Registry(NARBDR).

Steel to heal? MPD surgical conundrums

Efficacy and Safety of ReFacto AF for Surgical Hemostasis in Previously Treated Patients with Severe Hemophilia A.

von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate Is Safe and Effective for Management of Elective Surgery in Adults and Children with von Willebrand Disease (VWD): Combined Results of United States (US) and European (EU) Studies.

An Exercise Training Programme Produces Significant Improvements in Quality of Life (QoL), Muscle Strength and Cardiorespiratory Function in Patients with Myeloma.

A New Formulation of Recombinant Human Factor IX Is Bioequivalent to BeneFIX: A Double-Blind, Randomized, Crossover Pharmacokinetic and Open-Label Safety and Efficacy Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only